Sugi Predict

Sugi Predict / Compounds / SCHEMBL30874405

SCHEMBL30874405

SCHEMBL30874405

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C

nearest known ligand 0.64

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.64
▸ GLP1R P43220 10/20 0.63
▸ ECE1 P42892 1/20 0.63
▸ MUS81 Q96NY9 1/20 0.63
▸ PTH1R Q03431 7/20 0.62
▸ GCGR P47871 1/20 0.61
▸ GIPR P48546 1/20 0.61
▸ VIPR2 P41587 2/20 0.58
▸ VIPR1 P32241 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31093453 0.96 RXFP1 (0.69) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30874388 0.95 GLP1R (0.60) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30874394 0.95 RXFP1 (0.67) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30049211 0.94 RXFP1 (0.66) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30028445 0.94 PTH1R (0.69) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30183270 0.94 RXFP1 (0.70) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL29462132 0.94 RXFP1 (0.70) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL29848900 0.94 RXFP1 (0.67) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30028783 0.94 RXFP1 (0.67) RXFP1GLP1RECE1MUS81PTH1R
SCHEMBL30618467 0.94 RXFP1 (0.60) RXFP1GLP1RECE1MUS81PTH1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150423-A1 GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150423-A1 GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES GLP1R, IAPP, GCG RXFP1 271/4885GLP1R 1/4885ECE1 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.